Nanogels as Pharmaceutical Carriers: Finite Networks of Infinite Capabilities by Vinogradov, Serguei V. & Kabanov, Alexander V.
Drug Delivery
DOI: 10.1002/anie.200900441
Nanogels as Pharmaceutical Carriers: Finite Networks of
Infinite Capabilities
Alexander V. Kabanov* and Serguei V. Vinogradov
Angewandte
Chemie
Keywords:
drug delivery · nanogels ·
polyelectrolytes · polymers ·
polynucleotides
In memory of Viktor A. Kabanov (1934–2006)
A. V. Kabanov and S. V. VinogradovReviews
5418 www.angewandte.org  2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2009, 48, 5418 – 5429
1. Introduction
The term “nanogels” usually defines aqueous dispersions
of hydrogel particles formed by physically or chemically
cross-linked polymer networks of nanoscale size. We intro-
duced this term to define the swollen chemically cross-linked
networks of cationic and neutral polymers such as the
branched PEG-cl-PEI made from polyethylenimine (PEI)
and poly(ethylene glycol) (PEG) which was initially designed
for the delivery of antisense oligonucleotides.[1,2] However,
prior to our work the research group of Sunamoto described
the phenomenon of the physical cross-linking (self-assembly)
of cholesterol-modified polysaccharides (for example, pullu-
lan, mannan, amilopectin and dextran), which resulted in the
formation of swollen hydrogels of nanoscale size;[3] a review
on this type of systems was recently published.[4] Technically,
these systems are also nanogels, and we will refer to them as
nanogels here.
Nanogels are very promising as drug-delivery carriers
because of their high loading capacity, high stability, and
responsiveness to environmental factors, such as ionic
strength, pH, and temperature that are unprecedented for
common pharmaceutical nanocarriers. Since the first review
on synthesis and application of nanogels published in 2002,[5]
this novel family of nanoscale materials has attracted
increasing attention for the delivery of drugs, biomacromol-
ecules and imaging agents. The present paper provides an
updated overview of pharmaceutical use and potential of
nanogels. We also recommend recent reviews for additional
reference on synthesis and applications of nanogels.[6,7]
Unloaded nanogels in a swollen state contain consider-
able amount of water. Loading of biological agent(s) is
usually achieved spontaneously through electrostatic, van der
Waals and/or hydrophobic interactions between the agent and
the polymer matrix. As a result, the nanogels collapse forming
stable nanoparticles, in which biological agent becomes
entrapped. The aggregation of nanogels can be prevented
by introducing dispersing hydrophilic polymers, such as
poly(ethylnene glycol) (PEG) in their structure. During the
collapse of the drug-nanogel complex such polymers become
exposed at the surface and form a protective hydrophilic layer
around the nanogel that prevents phase-separation. The
functional groups at the nanogel surface can be additionally
modified with various targeting moieties for site specific drug
delivery in the body. Various nanogels have been shown to
deliver their payload inside cells and across biological
barriers. Such nanogels exhibit high stability and protect
biological agents from degradation by cells metabolic
systems. Overall nanogels demonstrate excellent potential
for systemic drug delivery and enhancing oral and brain
bioavailability of low-molecular-weight drugs and biomacro-
molecules.
2. Preparation of Nanogel Networks
Current approaches used for the preparation of nanogels
can be divided into 1) physical self-assembly of interactive
polymers; 2) polymerization of monomers in a homogeneous
phase or in a micro- or nanoscale heterogeneous environ-
Nanogels are swollen nanosized networks composed of hydrophilic
or amphiphilic polymer chains. They are developed as carriers for the
transport of drugs, and can be designed to spontaneously incorporate
biologically active molecules through formation of salt bonds,
hydrogen bonds, or hydrophobic interactions. Polyelectrolyte nano-
gels can readily incorporate oppositely charged low-molecular-mass
drugs and biomacromolecules such as oligo- and polynucleotides
(siRNA, DNA) as well as proteins. The guest molecules interact
electrostatically with the ionic polymer chains of the gel and become
bound within the finite nanogel. Multiple chemical functionalities can
be employed in the nanogels to introduce imaging labels and to allow
targeted drug delivery. The latter can be achieved, for example, with
degradable or cleavable cross-links. Recent studies suggest that
nanogels have a very promising future in biomedical applications.
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ment; 3) cross-linking of preformed polymers; and 4) tem-
plate-assisted nanofabrication of nanogel particles. These
methods are illustrated in Figures 1–4 and described below.
The physical self-assembly of polymers was used by
several research groups to produce various nanogels. This
method usually involves controlled aggregation of hydro-
philic polymers capable of hydrophobic or electrostatic
interactions and/or hydrogen bonding with each other. The
preparation of nanogels is conducted in mild conditions and in
aqueous media. Self-associating hydrophilic polymers allow
encapsulation of biomacromolecules, and are useful for the
preparation of protein-loaded nanogels. For example,
Akiyoshi et al. prepared hydrogels by the hydrophobic
association of cholesterol-modified pullulan in the presence
of insulin (Figure 1a).[8] The nanogels formed in a narrow
range of cholesterol/sugar units ratio (1:40–1:100) with a
diameter of 20–30 nm and contained up to five insulin
molecules per particle. The sizes of the self-assembled
nanogels are controlled by appropriate selection of the
concentration of the polymers and environmental parameters,
such as the pH value, ionic strength, and temperature. For
example, Yu et al. prepared protein nanogels by temperature-
induced gelation of oppositely charged proteins, such as
ovalbumin and lysozyme or ovotransferrin.[9] Similarly, nano-
gels were obtained by pH- and temperature-induced gelation
of chitosan and ovalbumin.[10] A study byGref and co-workers
described the self-assembly of nanogels of various sizes by
association of a lauryl-modified dextran and a b-cyclodextrin
polymer in aqueous media (Figure 1b).[11] Gels of about 120–
150 nm were obtained by variation of the two polymers over a
wide concentration range. The resulting nanogels were stable
and withstood freeze-drying, which was found to be a
convenient method for their long-time storage.
Chemical synthesis in heterogeneous colloidal environ-
ments can generally provide opportunities to vary the
structure and properties of the nanogel. Few studies used
inverse water/oil (w/o) microemulsions as a medium for the
polymerization of monomers, with bifunctional monomers
added as cross-linkers to ensure formation of stable nanoscale
networks (Figure 2a). Speiser et al. were the first to carry out
the copolymerization of monomers in reverse micelles.[12]
Their approach was extended by Levashov and co-workers
to covalently immobilize enzymes in polymeric nanogranules
of acrylamide and N,N-methylenebisacrylamide copoly-
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Figure 1. Physical self-assembly of nanogels in aqueous media.
a) Aggregation of the hydrophobically modified polymer cholesterol-
pullulan in the presence of insulin molecules results in nanogels
containing entrapped protein. b) Mixing of lauryl-modified dextran and
a b-cyclodextrin polymer results in the formation of nanogels stabilized
through the host–guest binding of the b-cyclodextrin and lauryl
moieties.
Figure 2. Chemical synthesis of nanogels by copolymerization in
colloidal environments. a) Copolymerization of monomers (1) and
bifunctional cross-linkers (2) in w/o microemulsions stabilized by
surfactants (3) produces nanogels that can then be transferred into
aqueous media after removal of the surfactants and organic solvent.
b) Copolymerization reactions can also be carried out in o/w emul-
sions that can be additionally stabilized by surfactants.
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mers.[13] Subsequently, DeSimone and co-workers prepared
cationic PAETMAC nanogels by inverse microemulsion
polymerization of 2-acryloxyethyltrimethylammonium chlo-
ride and 2-hydroxyethylacrylate in heptane with PEG-bis-
acrylate used as a bifunctional cross-linker.[14,15] Anionic
nanogels with particle hydrodynamic diameters as small as
50 nm were also prepared by copolymerization of poly(dime-
thylacrylamide-co-2-acrylamido-2-methyl-1-propanesulfonic
acid) and the N,N-methylenebisacrylamide cross-linker in an
inverse microemulsion.[16]
Labile bonds are frequently introduced into nanogels
during polymerization to make them degradable and facili-
tate drug release. For example, Frchet and co-workers
reported a free-radical polymerization in an inverse emulsion
that led to the preparation of degradable acrylamide-based
nanogels containing acid-labile acetal cross-linkers for pro-
tein, antigen, and DNA delivery.[17] The acetal group is stable
at pH 7 (t1/2= 24 h), but rapidly hydrolyzes at acidic endo-
somal pH values (t1/2= 5 min), which results in degradation of
the nanogel and facilitates the release of the payload.[18,19] The
Matyjaszewski research group used atom-transfer radical
polymerization (ATRP) in an inverse microemulsion for the
synthesis of stable cross-linked nanogels of water-soluble
polymers.[20] They used a disulfide-functionalized cross-linker
to synthesize biodegradable nanogels. Disulfide groups are
stable in extracellular media but cleave inside cells because of
the presence of glutathione. This may also facilitate the
release of the nanogel payload inside the cells. Matyjaszewski,
Kataoka, and co-workers further extended this approach to
the synthesis of biodegradable, cross-linked poly-
[oligo(ethylene oxide)-methyl methacrylate] nanogels.[21]
Polymerization reactions that result in the formation of
nanogels can also be carried out in o/w emulsions or aqueous
suspensions (Figure 2b). Furthermore, the polymerization
can be started in a homogeneous aqueous solution of water-
soluble monomers, which results in the formation of a
colloidal suspension of the growing polymer. For example,
Peppas and co-workers synthesized a suspension of nano-
spheres composed of PEG-grafted poly(methacrylic acid)
(PMA) in water by using a UV-initiated solution/precipitation
polymerization method.[22]
In addition to these polymerization methods, covalent
cross-linking of preformed polymer chains provide excellent
opportunities for producing nanogels with large pore sizes.[23]
The cross-linking method was widely used for the synthesis of
a variety of functional nanogels for drug delivery. In
particular, it was used to synthesize the first cross-linked
cationic nanogel for polynucleotide delivery.[1] In this case, a
doubly activated PEG was conjugated to a branched PEI in
an o/w emulsion (dichloromethane in water), followed by
evaporation of the solvent in vacuo and maturation of the
nanogel in an aqueous solution (Figure 3a). Cationic PEI-
containing nanogels of 80–200 nm diameter were also
obtained by the photo-Fenton reaction in aqueous
media.[24,25] Small (40–45 nm) nontoxic cross-linked pullulan
nanogels were prepared in the reverse micellar system
(aerosol OT/hexane).[26,27] Similar to the case of polymeri-
zation reactions, the cross-links that connect the polymeric
chains in such nanogels can bemade degradable. For example,
a biodegradable segmented PEI connected by disulfide
linkers was used to prepare cationic nanogels for polynucle-
otide delivery with reduced toxicity.[28,29] In another study
hyaluronic acid (HA) nanogels containing biodegradable
disulfide linkages were prepared by the inverse w/o emulsion
method.[30] An interesting type of cross-linked nanogels
containing DNAwas obtained by mixing thiol-functionalized
six-arm-branched PEG and DNA in dimethyl sulfoxide,
which produced particles of 100 nm diameter. These nano-
particles were then cross-linked by oxidation to obtain DNA-
loaded biodegradable nanogels.[31]
Unprecedented opportunities for the control of the spatial
distribution of polymeric chains at the nanoscale are provided
by combining the controlled self-assembly of polymeric
micelles and cross-linking techniques. For example, Wooley
and co-workers have chemically linked the shell layers of
polymeric micelles to obtain various shell-cross-linked nano-
particles.[32–37] By adjusting factors that affect the morphology,
such as solvents and organic counterions, they produced an
array of different cross-linked nanostructures including
spheres, rods, and even toroids.
In another study, PEI was cross-linked in aqueous solution
to the micelles of doubly activated pluronic triblock copoly-
mer (PEG-b-PPG-b-PEG; Figure 3b; PPG = poly(propy-
Figure 3. Synthesis of nanogels by cross-linking of the preformed
polymer chains or self-assembled polymeric aggregates. a) Cross-link-
ing of PEG and PEI chains with two activated termini in an o/w
emulsion followed by evaporation of the organic solvent. b) Conjuga-
tion of PEI to an activated pluronic block copolymer (PEG-PPG-PEG)
with two activated termini which self-assembles into polymeric
micelles in aqueous solution results in nanogels containing hydro-
phobic PPG domains and a cross-linked PEI-PEG network. c) The
diblock copolymer PEG-b-PMA contracts in the presence of divalent
metal cations in an aqueous solution into a micelle with a polyion-
metal core and a PEG corona. This is followed by cross-linking of the
micelle core and removal of the metal cations, which results in
nanogels with a cross-linked polyanion (PMA) core and a PEG corona.
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lene glycol)).[38] This produced nanogels with a hydrophobic
PPO core surrounded by a swollen cross-linked PEI and a
PEO shell (PEG-cl-PEI). Lee et al. photo-cross-linked the
polymeric micelles of poly(d,l-lactic acid)-b-PEG-b-poly(d,l-
lactic acid) with acrylate end groups.[39] As a result, nanogels
were formed which contained self-assembled hydrophobic
domains of micelles with insoluble poly(d,l-lactic acid) cores,
which could be loaded with a hydrophobic anticancer drug.
A unique control of spatial distribution of polymer chains
in a nanogel was achieved by Bronich et al.[40] They developed
a procedure in which polyelectrolyte micelles were initially
prepared by the self-assembly of ionic blocks of double
hydrophilic block copolymers with an oppositely charged
condensing agent. This was followed by chemical cross-
linking of ionic blocks in the core and removal of the
condensing agent (Figure 3c). The resulting nanogels made
from PEG-b-poly(methacrylic acid) (PEG-b-PMA) diblock
copolymers contained a hydrophilic PEG shell and a cross-
linked hydrophilic PMA ionic core which swell in water and
can incorporate hydrophilic drugs.[41] A similar technique was
also used to prepare core-shell nanogels by the condensation
and cross-linking of PEG-grafted poly(acrylic acid) (PEG-g-
PAA).[40]
Finally, DeSimone and co-workers developed a novel
method for the fabrication of polymeric particles with sizes on
the order of tens of nanometers to several micrometers, which
can be used for the synthesis of nanogels.[42] This imprint
photolithographic technique (particle replication in Nonwet-
ting templates PRINT) uses nonwetting elastomeric molds of
a low surface energy perfluoropolyether network prepared on
patterned silicon templates by photochemical cross-linking of
dimethacrylate-functionalized perfluoropolyether oligomers.
The nonwetting molds eliminate the formation of a residual
interconnecting film between the molded objects, thus allow-
ing the production of monodisperse, shape-specific nano-
particles from an extensive array of organic precursors
(Figure 4). This method enables strict control over the
particle size, shape, composition, and surface functionality,
and permits the loading of delicate cargos, including pharma-
ceutical drugs and biomacromolecules. For example, mono-
disperse 200 nm PEG-based swellable particles were fabri-
cated with the PRINT method by UV-induced copolymeriza-
tion of several vinyl monomers such as PEG triacrylate, PEG
monomethyl ether monomethacrylate, and p-hydroxystyr-
ene.[43]
Many studies have used one of the basic procedures
described above to prepare increasingly sophisticated types of
nanogels. For example, a nanostructured thermosensitive
hydrogel based on an interpenetrating network of poly-(N-
isopropylacrylamide) (PNIPAAm) was immobilized on
porous silica gel and hydroxyapatite.[44,45] Richtering and co-
workers used the layer-by-layer deposition of polyelectrolyte
multilayers at the surface of an anionic PNIPAAM-co-PMA
nanogel to prepare thermosensitive core-shell materials.[46,47]
Layer-by-layer deposition can be used to introduce various
materials, such as magnetic nanoparticles, at the surface of the
nanogels.[48]
Another interesting type of hybrid nanogels covered by a
lipid bilayer was recently introduced by the Levon and
Hennink research groups.[49,50] They prepared liposomes
loaded with a water-soluble monomer, which was then
polymerized by photoinitiation to form a network of poly-
acrylamide (PAA) within the inner cavity of the liposome.
Yan et al. produced catalytic nanogels encapsulating horse-
radish peroxidase or bovine carboxyanhydrase by polymeri-
zation of PAA andN,N-methylenebisacrylamide on the sur-
face of a single enzyme molecule.[51,52] The enzymes main-
tained their catalytic activity and exhibited high thermal
stability as a result of immobilization within the nanogel
particles. In other studies PEGylated nanogels embedded
with metal nanoparticles were synthesized by Oishi et al.[53,54]
Such hybrid nanogels containing Pt nanoparticles (< 2 nm)
have shown catalytic activity which is dependent on the
pH value, and can be used as scavengers of reactive oxygen
species in biological and medicinal applications. The nanogels
containing Au nanoparticles (ca. 6 nm) exhibited a shift of the
surface plasmon resonance (SPR) band in response to a
change in the pH value. Such nanogels may be adopted as
SPR probes in various types of sensors. Finally, the photo-
chemical emulsion-free polymerization on the surface of
superparamagnetic ferrous oxide nanoparticles in aqueous
solution was used for the preparation of composite super-
paramagnetic nanogels,[55,56] which may be used for micro-
wave ablation therapy.[57]
Future developments in the preparation of chemically or
physically cross-linked nanogels may include the use of
micropflidic techniques, which have shown promise in the
preparation of micrometer-sized hydrogels and nanomaterials
of different sizes, shapes, and morphologies.[58,59]
Figure 4. Nonwetting elastomeric perfluoropolyether molds are used
in the photolithographic technique PRINT to produce monodisperse,
shape-specific nanoparticles from various organic precursors.
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3. Chemical Modification of Nanogels for Site-
Specific Drug Delivery
Nanocarriers can be delivered to disease-affected sites
after injection in body fluids. Major impediments to this
delivery strategy include: 1) the interaction of nanocarriers
with serum proteins, thereby resulting in opsonisation or
agglutination; 2) the clearance of the nanocarriers by the
reticuloendothelial system (RES) or through kidney glomer-
ules, and 3) nonspecific accumulation in organs. To reduce the
interaction with serum proteins and extend circulation time,
the nanocarrier surface is often modified with inert hydro-
philic polymers, such as PEG.[60] For example, drug-loaded
PEG-cl-PEI nanogels have a core-shell architecture in which
the core is surrounded by PEG chains.[61] Similarly, PEG
chains can be tethered to polymethacrylate nanogels during
the emulsion polymerization procedure.[62] Nanogels with
cross-linked cores and PEG corona can be produced by the
self-assembly of polyelectrolyte micelles followed by cross-
linking of the cores.[40]
A recent study characterized the in vivo pharmacokinetics
and biodistribution of PEG-based cross-linked nanogel
cylinders (ca. 200 nm) obtained with the PRINT technique.[43]
The particles were cleared relatively rapidly from the blood
(t1/2= 17 min) and accumulated in the liver. This result was
not surprising since the nanogels contained relatively short
PEG chains (ca. 1 kDa), while the optimal coating for long-
circulating nanoparticles would have PEG between 2 and
5 kDa.[63]
The nanogel “surface” can also be decorated with
biospecific targeting groups, which can enhance the site-
specific delivery of the nanogels in the body. For example, we
described biotinylated PEG-cl-PEI nanogels that were vec-
torized with (strepta)avidin by biotinylated ligands (trans-
ferrin or insulin).[64] Biotin groups were also attached to OH-
functionalized poly[oligo(ethylene oxide)-methyl methacry-
late] nanogels.[21] However, biotin-(strepta)avidin conjugation
is not practical because of the biological activity of biotin.
Hence, it is preferable to directly conjugate the targeting
groups to the nanogels. For example, after carbodiimide
activation, 1–5% of the primary amino groups of a PEG-cl-
PEI nanogel were modified with folic acid.[61] These folate-
modified nanogels exhibited a noticeable increase in the
transport across a gastrointestinal model barrier (Caco-2 cell
monolayers) in vitro. In another study, polymethacrylate
microgels modified with folate demonstrated increased and
selective cellular uptake in cancer cells overexpressing folate
receptors (FR).[65] To reduce problems associated with the
accessibility of folate to its cellular receptors, several research
groups recommended insertion of a polymer linker (for
example, PEG) between the folate moiety and drug carrier.[66]
For example, the terminal amino groups of PEG in a
poly(aminoPEG-cyanoacrylate-co-hexadecyl cyanoacrylate)
nanogel were modified with folic acid.[67] Such folate-deco-
rated nanogels also demonstrated enhanced accumulation in
FR-overexpressing cancer cells.
Nanogels were also conjugated with human transferrin
(hTf), a tumor-targeting protein.[68] In this method, amino
groups in hTf were first treated with the heterofunctional
reagent sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohex-
ane-1-carboxylate in an aqueous medium to obtain a mal-
eimide derivative of hTf. In a second step, thiol groups were
then introduced into the PEG-cl-PEI nanogels by reaction
with 2-iminothiolane (Trouts reagent). Finally, the reaction
between maleimide-hTf and the thiol groups of the nanogel
led to the formation of hTf-decorated nanogels with a
controlled number of hTf molecules (from 4 to 12) per
particle. The large size of the conjugated hTf resulted in it
being exposed at the nanogel surface, which facilitated its
interaction with cellular transferrin receptors.
Additionally, peptide ligands can be attached to nanogels
through a bifunctional PEG linker.[28] For example, a peptide
with terminal cysteine groups was conjugated to a maleimide-
PEG-N-hydroxysuccinimide linker. The product was then
reacted with the amino groups of PEI to obtain a decorated
nanogel with the required peptide density. Finally, a mono-N-
acetylcystamine-PEG linker was introduced into nanogels by
1,1’-carbonyldiimidazole activation; the thiol groups on the
nanogels were unmasked with dithiothreitol and treated with
the thiol-specific (for example, maleimide) derivatives to
yield the protein/peptide-modified nanogels.[69]
In summary, nanogels provide numerous possibilities for
their surfaces to be decorated with various targeting groups.
Initial evidence suggests that these approaches can be used to
transport nanogels to selected cellular receptors.
4. Swelling: The Most Important Property of
Nanogels
Nanogels are soft nanomaterials. The swelling of nanogels
in an aqueous environment is controlled by both 1) the
nanogel structure (chemical structure of the polymer, degree
of cross-linking, charge density in the polyelectrolyte gels),
and 2) environmental parameters, such as pH value, ionic
strength, and chemical nature of low-molecular-mass ions for
polyelectrolyte gels as well as temperature for thermores-
ponsive gels (Figure 5). It is well known that a balance
between the osmotic pressure and the polymer elasticity
determines the physical dimensions of a hydrogel particle.[70]
The osmotic pressure of polyelectrolyte hydrogels results
from the net difference in the concentration of mobile ions
between the interior of the gel particle and the exterior
solution. The ionized groups attract hydrated counterions.
This favors the swelling of the gel, while the entropy elasticity
of the polymer chains opposes the expansion. The ionization
of weak polyelectrolyte gels depends on the pH value. A
reduction in the total charge and number of counterions as
the pH changes results in compression of the gel (because of
decreased osmotic pressure) until the excluded volume of the
polymer chains limits further compression. For example,
cross-linked PEG-b-PMA nanogels compressed as the
pH value decreased from 9 to 5 as a result of protonation of
the carboxylate groups of PMA.[41] Likewise, the PEG-cl-PEI
nanogel compressed as the pH value increased from 8.5 to 10
through deprotonation of the PEI amino groups.[71]
The swelling of polyelectrolyte hydrogels also depends on
the ionic strength. For example, at high ionic strength, the
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swelling of cationic PAETMAC nanogels is governed by the
concentration of the cross-linker, while at low ionic strength
the swelling is influenced by both the cross-linker and the
concentration of the charge.[14] As a general rule, the swelling
ratio of cross-linked hydrogels decreases as the number of
cross-links increases.[14,41] This was shown by using cross-
linked PEG-b-PMA nanogels as an example.[32]
In selected cases, the interactions between the solvent and
the polymer chains of the nanogels are temperature depen-
dent, and can lead to swelling or collapse of the gels. For
example, since PPG chains in pluronic polymers exhibit a
lower critical solution temperature (LCST), the pluronic-
based nanogels are temperature-responsive. For example,
small 120 nm nanogel particles were shown to swell drasti-
cally to over 400 nm upon a rapid decrease in the temperature
below the LCST.[72] A temperature dependence of the
swelling was also observed for nanogels of N-isopropylacry-
lamide (NIPAAm) copolymers.[45,73] This property can be
used to engineer stimuli-responsive drug carriers. One recent
example is glucose-sensitive phenylboronic acid conjugated
NIPAAm nanogels which have a swelling behavior that
depends on the glucose concentration.[74] One of the advan-
tages of highly dispersed hydrogels is that they usually
respond very rapidly to changing environmental conditions,[75]
which facilitates the incorporation and release of biological
agents in pharmaceutical applications. In contrast, the swel-
ling equilibrium for bulky hydrogels requires periods on the
order of days. In selected cases, the loading of drugs in the
hydrogel can additionally reduce the volume. One reason for
this is that the drug interacts with the hydrogel chains through
electrostatic binding, hydrophobic interactions, and/or hydro-
gen-bond formation, which decreases the “solubility” of the
hydrogel chains and results in contraction and collapse of the
gel. The swelling and collapse of nanogels are unique
properties for optimizing drug loading and release (see
Section 5).
5. Loading Nanogels with Drugs and Their Release
Biological agents can be incorporated in nanogels by
1) physical entrapment, 2) covalent conjugation, or 3) con-
trolled self-assembly. Physical entrapment was employed for
the incorporation of insulin in cholesterol-modified pullulan
nanogels[8] and siRNA in thiol-conjugated hyaluronic acid
nanogels.[30] The physical entrapment of drugs can also be
achieved by the complexation of dextrans with poly-l- and
poly-d-lactide side chains into monodisperse biodegradable
nanogel particles with an average diameter of 70 nm.[76] Such
nanogels contain hydrophilic dextran chains joined by
partially crystallized hydrophobic regions of noncovalently
bound chains of polylactide stereisomers.
In addition, hydrophobic molecules can be solubilized in
the hydrophobic domains present in some nanogels. For
example, prostaglandinE2 was solubilized in nanogels of
cholesterol-modified pullulan.[77] Doxorubicin was also
loaded in amphiphilic cross-linked nanogels based on plur-
onic F127[78] or poly[oligo(ethylene oxide)-methyl methacry-
late].[21] Notably, in most cases loading arising from hydro-
phobic interactions alone results in relatively low loading
capacities.
An example of the covalent attachment of a biological
agent to a nanogel is the loading of cisplatin in PEG-b-
PMA.[79,80] Such nanogels have a cross-linked polyanionic
(PMA) core and a neutral polymer (PEG) corona. In aqueous
solution cisplatin reacts with the carboxylic groups in the core
of the gels, which leads to collapse of the drug-loaded core.
Modification of enzyme molecules with N-hydroxysucci-
nimidoacrylate followed by polymerization of the acrylamide
in dilute aqueous solutions was used to obtain protein-
encapsulating polyacrylamide nanogels.[51,52] Alternatively,
polyacrylamide nanogels incorporating modified a-chymo-
trypsin were prepared by copolymerization in an inverse
microemulsion.[13] Such nanogels which contain covalently
bound proteins can increase the thermostability and shelf life
of the protein.[56]
A different approach based on the controlled self-
assembly of polyelectrolyte-based nanogels with oppositely
charged solutes can produce nanomaterials with a high
loading of biological agents. Various polyelectrolyte-based
nanogels were shown to interact with oppositely charged
surfactants, synthetic polyelectrolytes, polynucleotides, and
proteins in aqueous solutions.[1,69,71,81,82]
The self-assembly of such materials is usually character-
ized by high binding cooperativity and efficiency. The binding
of an anionic surfactant, such as sodium tetradecyl sulfate,
with cationic PEG-cl-PEI nanogels has an onset at a “critical
association concentration” (cac) which is two orders of
magnitude lower than the critical micelle concentration
Figure 5. Factors affecting nanogel swelling. a) An increase in the
amount of cross-linking decreases the swelling of the nanogels
comprised of a hydrophilic polymer. b) An increase in the pH value
results in the collapse of a nanogel comprised of weak polybase
chains, and the swelling of nanogels comprised of a weak polyacid.
c) An increase in the ionic strength decreases the swelling of polyelec-
trolyte nanogels. d) Nanogels comprised of polymers exhibiting LCST
behavior collapse as the temperature increases above the LCST.
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(cmc) of this surfactant alone.[71] Such a drastic difference in
these values is explained by cooperative stabilization of
surfactant aggregates as a result of electrostatic interactions
between the surfactant head groups and the PEI chains of the
nanogel. Charged and amphiphilic biological active molecules
such as sodium oleate, indomethacin, and retinoic acid were
also incorporated into PEG-cl-PEI nanogels.[71] For example,
nanogels loaded with retinoic acid formed nanosized dis-
persions that were stable at physiological pH and ionic
strength, and which could be lyophilized, stored, and then re-
dispersed. A similar formulation of the antiepileptic drug
valproic acid in PEG-cl-PEI nanogels was also obtained and
investigated in vitro.[69] Furthermore, hydrophobic regions
present in PEG-cl-PEI/surfactant complexes can serve as
non-aqueous reservoirs for solubilizing water-insoluble mol-
ecules. Since a combination of polyionic and hydrophobic
interactions stabilizes drug-nanogel formulations, anionic
compounds bearing only a few charges, for example, 5’-
triphosphates of nucleoside analogues, such as fludarabine,
zidovudine, cytarabine, and floxuridine, can also be efficiently
loaded into cationic nanogels.[29,38,61]
Recently, the properties and prospective applications of
this type of nanoformulations were reviewed.[83] In summary,
polyelectrolyte nanogels can be a versatile platform for the
incorporation of various small drug molecules through the
combination of electrostatic and hydrophobic interactions as
well as hydrogen-bond formation.
One of the most important features of weakly cross-linked
polyelectrolyte nanogels is their ability to incorporate bio-
macromolecules of the opposite charge. The accommodation
of biomacromolecules in hydrogels is usually hindered by the
excluded volume and cross-linking density. However, if the
biomacromolecules and polymer network have opposite
charges, they react effectively with each other to form a
polyelectrolyte complex. In the cases when the polyelectro-
lyte chains penetrate the nanogels, the process develops as a
frontal reaction between oppositely charged polyions and
spreads from the exterior of the gel to its core.[84] As a result,
efficient loading of biomacromolecules can be achieved even
with bulk polyelectrolyte networks (Figure 6).[85]
This principle has been exploited to immobilize polynuc-
leotides in cationic nanogels. Both PEG-cl-PEI and PAET-
MAC have been used to incorporate antisense oligonucleo-
tides.[1,14] The addition of oligonucleotides to a PEG-cl-PEI
nanogel dispersion at physiological pH resulted in the rapid
formation of polyelectrolyte complexes between the oligonu-
cleotide and the PEI. This process was accompanied by an
approximately 10-fold reduction in the nanogel volume
(“collapse”) by neutralization of the charges in the network.
Notably, the binding of the oligonucleotide with the nanogel
was almost complete, and the loading capacity of the nanogel
was 15 to 30 wt%. Interestingly, the oligonucleotide-loaded
nanogels remained stable in the presence of negatively
charged serum proteins, which can be explained by a higher
binding cooperativity between the oligonucleotide chains and
the polycation compared to the protein–oligonucleotide
binding.[86]
In general, higher drug-loading capacities can be expected
for hydrophilic nanogels than those normally observed for
other nanosized pharmaceutical carriers such as polymeric
micelles, liposomes, and biodegradable nanoparticles. The
main reason for this is that swollen nanogels are mainly
comprised of water and, therefore, provide a larger cargo
space for the incorporation of solutes, which is important in
the case of low-molecular-mass drugs and, especially, bio-
macromolecules. Furthermore, high loading in nanogels can
be achieved by self-assembly and under relatively mild
conditions compared to other carriers. This property is very
important for the preservation of the biological activity of
labile drugs and biomacromolecules, such as proteins and
polypeptides.
The biological agents can be released from nanogels
through 1) simple diffusion, 2) degradation of the nanogel;
3) a shift in the pH value, 4) displacement by counterions
present in the environment, or 5) transitions induced by an
external energy source (Figure 7). Examples include diffu-
sion-controlled release of doxorubicin from pluronic-based
hydrogels.[87] A similar release mechanism has been employed
in polymeric micelles which are already in clinical studies.[88]
There is also increased interest in developing nanogels that
can release biological agents in response to environmental
signals at the disease site. As already discussed, a change in
the pH value or the presence of a reducing environment can
serve as chemical signals that trigger the release. For example,
an acrylamide-based nanogel with acetal cross-links is stable
at an extracellular pH value of 7.4, but degrades and releases
entrapped protein at pH 5.0.[17] Similarly, the PEG-cl-PEI
nanogels with disulfide cross-links rapidly degraded in the
presence of a reducing agent.[28,29] Likewise, a poly-
[oligo(ethylene oxide)-methyl methacrylate] nanogel with
disulfide cross-links degraded in the presence of a glutathione
tripeptide commonly found in cells.[21] The degradation of
these nanogels was shown to trigger the release of the
Figure 6. Loading and release of biomacromolecules in a cross-linked
polymer hydrogel. A cross-linked gel comprised of neutral PEG and
anionic PAA polymer chains is immersed in a solution of a cationic
protein cytochrome c. The cytochrome c is spontaneously loaded into
the gel through the formation of a complex between the protein and
PAA chains. The gel collapses and acquires the red color of cyto-
chrome c, while the external solution becomes clear. Acidification or
addition of Ca2+ ions results in protein release as a result of either
deprotonation of the carboxylic groups of the PAA (acidification) or
competitive binding of the Ca2+ ions with the carboxylic groups of the
PAA. In both cases the external solution acquires the red color of
cytochrome c, while the gel further collapses.
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encapsulated low-molecular-mass solutes rhodamine 6G and
doxorubicin. In another study, the dissolution of disulfide
cross-linked HA nanogels and release of siRNAwas induced
by adding glutathione.[30] Clearly, the release kinetics can be
fine-tuned in each case by altering the number of cross-links.
Polyelectrolyte hydrogels that incorporate biological
agents through electrostatic bonds can also release biological
agents in response to environmental changes. For example,
pH-sensitive nanogels based on PAA can release an oppo-
sitely charged protein in tumor sites or endosomal compart-
ments upon acidification.[10,73,89,90] A different mechanism was
proposed for the release of nucleotide drugs from cationic
PEG-cl-PEI nanogels.[91] In this case, negatively charged
biomacromolecules bound to nanogels can be displaced by
negatively charged cellular components. For example, the
interaction of cationic nanogels with cellular membranes can
trigger the release of anionic 5’-triphosphates of nucleoside
analogues (NATP), as described in Section 6.[91]
In summary, the combination of the approaches presented
in Figure 7 can provide a very useful means for the control of
the drug-release characteristics of the nanogel carriers. In the
case of regular non-cross-linked polymeric micelles, drug
release to the external environment is controlled by two
factors.[92] The first is the strength of the binding of the drug in
the micelle core (whether hydrophobic or electrostatic) which
is characterized by drug partitioning between the external
environment and the micelle. The second is the binding of the
polymer chains in the micelles to each other, as characterized
by the cmc. Both factors are considered in terms of
“thermodynamic” and “kinetic stability”.[88,93] The small
sizes of the micelle core and shell results in the diffusion of
drugs from the micelles not usually being rate-limiting (at
least for low-molecular-mass drugs). As a result, the thermo-
dynamic and kinetic stabilities of drug–micelle constructs are
interrelated, that is, the stronger the binding, the slower the
release. As a rule, polymeric micelles are less stable than
liposomes or nanoparticles made of degradable polymers, and
hence the rates of release from micelles are faster. Nanogels
provide the means to fill the gap between these different
carrier types. For example, drug release can be decreased by
cross-linking the polymer chains in the nanogels, and it can be
adjusted and made responsive to environmental changes by
introducing cleavable cross-links. Furthermore, this technol-
ogy offers the possibility to control the drug-release profiles.
In contrast to liposomes and insoluble nanoparticles, the
hydrophilic nanogels swell as the drug is released, which
should sustain the release of the drug from the inner layers of
the nanogels as the amount released increases. This can be
used to modify or eliminate batch release or even to achieve
zero-order release kinetics of the drug from nanogels
delivered to the disease site.[74,94]
6. Delivery of Small Therapeutic Agents Using
Nanogels
Significant progress has been made in the application of
nanogels to the delivery of small therapeutic agents. As
already mentioned, retinoic acid was encapsulated into PEG-
cl-PEI nanogels.[71] In a similar manner, valproic acid was
formulated in PEG-cl-PEI nanogels.[69] In this case the
transport of the nanogels with valproic acid across a blood
brain barrier (BBB) model in vitro was investigated. The
permeability of the nanogels loaded with valproic acid across
bovine brain microvessel endothelial cells (BBMEC) mono-
layers was increased by at least 70% compared to a free drug.
This finding suggests that this formulation may be useful for
the delivery of valproic acid to the brain.
In another study, N-hexylcarbamoyl-5-fluorouracil, an
anticancer prodrug of 5-fluorouracil (5-FU), was encapsu-
lated in poly(N-isopropylacrylamide)-co-poly(N-vinylpyrro-
lidone) (PNIPAAm/VP) nanogels coated with polysor-
bate 80.[95] Drug release from this carrier was pH- and
temperature-dependent.[96] These nanogels were shown to
accumulate in rabbit brains. In another study, the anti-
leishmaniasis drug arjunglucoside I was also loaded into
PNIPAAm/VP nanogels.[97] This formulation showed
Figure 7. Drug release from nanogels. a) Diffusion of the drug from
nanogels. b) Drug release through degradation of the biodegradable
polymer chains or cross-links. c) A change in the pH value results in
deionization of the polymer network and the release of the electrostati-
cally bound drug. d) Multivalent low-molecular-mass cations or poly-
ions of positive or negative charge can displace drugs having the same
charge sign from electrostatic complexes with an ionic nanogel.
e) Drug release can be induced by the application of external energy to
the nanogels which induces degradation or structural transition of the
nanogel polymer chains.
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enhanced therapeutic efficacy against parasites as well as
reduced hepatotoxicity and nephrotoxicity compared to free
drugs.
A promising application of nanogels involves the delivery
of NATPs. These nucleoside-based anticancer and antiviral
agents usually enter cells via specific nucleoside transporters
and then undergo intracellular activation through 1) phos-
phorylation into nucleoside 5’-phosphates by intracellular
nucleoside kinases, 2) formation of nucleoside 5’-diphos-
phates; 3) conversion of ribonucleotides into deoxyribonu-
cleotides by nucleoside reductases, and finally 4) synthesis of
NATP.[98] The latter are actual active molecules, which arrest
DNA replication and transcription. The low efficiency of
conversion of the nucleosides into NATPs has resulted in
many prospective molecules being withdrawn at preclinical or
clinical stages of drug development. However, by using PEG-
cl-PEI nanogels as carriers it became possible to directly
deliver NATPs into cancer cells.[83] Nanogel-encapsulated
NATPs demonstrated enhanced cytotoxic activities in many
cancer cell lines and inhibited tumor growth in the mammary
carcinoma animal model.[99] Furthermore, an antiviral NATP,
5’-triphosphorylated ribavirin in a nanogel formulation,
exhibited higher activity in MDCK cells infected with
influenza A virus compared to a non-phosphorylated ana-
logue.[29] Interestingly, this formulation also demonstrated a
significantly reduced mitochondrial toxicity.
7. Biomacromolecules in Nanogels
There are several examples of the delivery of biomacro-
molecules in vitro or in vivo using nanogels.[1] Perhaps most
remarkably, nanogels loaded with oligonucleotides were
shown to cross cellular barriers. In particular, the incorpo-
ration of a phosphorothioate oligonucleotide into a cationic
PEG-cl-PEI nanogel resulted in a drastic increase in the
transcellular permeability of the oligonucleotide in polarized
Caco-2 cell monolayers used as an in vitro model of gastro-
intestinal epithelium.[1] The permeability of cell monolayers
with respect to 3H-mannitol, a paracellular marker, was,
however, not affected. This finding suggested that the
oligonucleotide-loaded nanogel was transported across the
cells, rather than passively diffused by a paracellular route.
Furthermore, in contrast to a free oligonucleotide, which was
essentially degraded in cells, the oligonucleotide in the
nanogels was protected against degradation. This study thus
indicates that nanogels are promising carriers for the oral
delivery of oligonucleotides.
Moreover, another study evaluated the transport of a
phosphorothioate oligonucleotide encapsulated in a PEG-cl-
PEI nanogel across the blood–brain barrier (BBB).[64] This
study showed that the oligonucleotide–nanogel complex was
transported effectively across polarized BBMECmonolayers,
which served an in vitro model of the BBB. Permeability was
further increased when the surface of the nanogel was
modified with bovine transferrin or insulin. These two
proteins target specific receptors at the blood side of the
brain epithelium and facilitated transport of the loaded
nanogels across the BBB to the brain side. Importantly, as in
the previous example, the oligonucleotide was transported by
a transcellular pathway and remained intact and incorporated
in the nanogels after release at the brain side. Biodistribution
studies in a mouse model further demonstrated that accumu-
lation of the oligonucleotide–nanogel complex in the brain
1 h after intravenous injection was increased nearly 15-fold
compared to the free oligonucleotide. Overall, this study
suggested that cationic nanogels have the potential to deliver
oligonucleotides to the brain.
Similar to oligonucleotides, a plasmid DNA immobilized
in cationic nanogels can be protected from enzymatic
degradation by extracellular and intracellular nucleases.
Furthermore, such nanogels can be used to deliver genes
into a cell. For example, a transferrin-modified PEG-cl-PEI
nanogel loaded with a plasmid DNA was shown to transfect
cells in a serum-containing medium.[69] Interestingly, the
dimensions of supercoiled DNA are comparable to those of
nanogel networks, which in a swollen state have a hydro-
dynamic diameter between 100 and 200 nm. It is unlikely,
therefore, that the plasmid DNA can percolate deep into the
pores of the cross-linked nanogels. A flexible cationic net-
work is probably capable of “wrapping around” supercoiled
DNA following the initial binding of the DNA with the
charged nanogel surface.
There is emerging interest in the pharmacological effects
of polymer excipients and nanomaterials in combination with
drugs.[100] In particular, synthetic polymers were shown to
interact with some drug transport systems and activate
selected cell-signaling pathways, and this was shown to alter
pharmacological, genomic, and immune responses to biolog-
ical agents.[79,80] Along similar lines, Frchet and co-workers
used acid-degradable nanogels for antigen presentation
in vitro and vaccination in vivo.[17,19,101–103] They have shown
that nanogels can be designed to generate immune responses
when delivered to phagocytic cells of the immune system. For
example, a plasmid DNA incorporated in nanogels with acid-
labile cross-linkers induced secretion of cytokine IL-6 and
immunostimulation of macrophages.[18] In another study, the
incubation of these nanogels loaded with ovalbumin (as a
model antigen) with dendritic cells derived from bone
marrow resulted in enhanced presentation of ovalbumin-
derived peptides.[101] It was also shown that adjuvant mole-
cules such as CpG oligonucleotides and anti-interleukin-10
oligonucleotides can be co-delivered with the protein antigen
for maximized cellular immune response.[103] Taken together,
these studies suggest that nanogels may be useful as delivery
and immune response modulating vehicles for the develop-
ment of DNA and peptide vaccines.
8. Conclusions
In conclusion, nanogels form a distinct class of hydrophilic
dispersed drug carriers with promising properties for encap-
sulating small biologically active agents and biomacromole-
cules. The advantages of these systems include their simplicity
of formulation, high loading capacity, and the stability of the
resulting dispersion. The swelling and collapse properties of
the nanogels are unique and provide multiple benefits for
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engineering optimal drug loading and release of drugs.
Nanogel networks are responsive to external environmental
factors, can undergo rapid volume changes, and allow for
stimuli-controlled release of encapsulated biologically active
compounds including charged or hydrophobic drugs and
biopolymers.
Furthermore, nanogels can be chemically modified to
incorporate various ligands for targeted drug delivery,
triggered drug release, or preparation of composite materials.
Preclinical studies suggest that nanogels can be used for the
efficient delivery of biopharmaceuticals in cells as well as for
increasing drug delivery across cellular barriers. It is clear that
there is no universal delivery system that can address all the
needs of current and future drug therapies. In this regard, the
capabilities of nanogels as well as other classes of pharma-
ceutical carrier are not infinite, but for humans “infinite”
often means beyond ones imagination.
We certainly hope that future application of nanogels as
pharmaceutical carriers will exceed our expectations and
believe that many capable scientists across the globe will
contribute outstanding work to advance these novel carriers
for practical use.
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